Provided by Tiger Trade Technology Pte. Ltd.

Rhythm Pharmaceuticals Inc.

98.07
-1.0800-1.09%
Post-market: 97.70-0.3653-0.37%18:11 EST
Volume:983.20K
Turnover:96.30M
Market Cap:6.54B
PE:-31.58
High:103.25
Open:103.25
Low:95.63
Close:99.15
52wk High:122.20
52wk Low:45.91
Shares:66.74M
Float Shares:53.42M
Volume Ratio:1.42
T/O Rate:1.84%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1057
EPS(LYR):-4.3376
ROE:-85.79%
ROA:-26.74%
PB:43.98
PE(LYR):-22.61

Loading ...

Sector Update: Health Care Stocks Retreat Friday Afternoon

MT Newswires Live
·
Nov 08, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Novo Nordisk, Block, Peloton Interactive

Reuters
·
Nov 08, 2025

BUZZ-U.S. STOCKS ON THE MOVE-ANI Pharmaceuticals, Wendy's, nLIGHT

Reuters
·
Nov 07, 2025

BUZZ-Rhythm falls after US FDA delays decision on drug for brain damage-related obesity

Reuters
·
Nov 07, 2025

Rhythm Pharmaceuticals Shares Down 3.5% Premarket After US FDA Extends Review of Co's Brain Damage-Related Obesity Drug

THOMSON REUTERS
·
Nov 07, 2025

FDA Extends Review of Rhythm Pharmaceuticals' IMCIVREE for Acquired Hypothalamic Obesity

Reuters
·
Nov 07, 2025

Rhythm Pharmaceuticals: FDA in Oct Requested Additional Sensitivity Analyses of Efficacy Data From Phase 3 Trial in Acquired Hypothalamic Obesity

THOMSON REUTERS
·
Nov 07, 2025

Rhythm Pharmaceuticals Inc: Major Amendment Did Not Include Any Information Relating to Safety or Manufacturing of Setmelanotide

THOMSON REUTERS
·
Nov 07, 2025

Rhythm Pharmaceuticals Announces FDA Extension of Review Period for Imcivree® (Setmelanotide) for Patients With Acquired Hypothalamic Obesity

THOMSON REUTERS
·
Nov 07, 2025

Rhythm Pharmaceuticals Inc: FDA Sets Updated Pdufa Goal Date of March 20, 2026

THOMSON REUTERS
·
Nov 07, 2025

Rhythm Pharmaceuticals Inc - Announces Listing Agreements in Five Canadian Provinces

THOMSON REUTERS
·
Nov 06, 2025

Rhythm Pharmaceuticals Announces Public Reimbursement for Imcivree® (Setmelanotide) in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program

THOMSON REUTERS
·
Nov 06, 2025

Rhythm Pharmaceuticals Secures Public Reimbursement for IMCIVREE in Five Canadian Provinces and Under NIHB Program

Reuters
·
Nov 06, 2025

Stock Track | Rhythm Pharmaceuticals Plummets 5.65% Following Oppenheimer Downgrade

Stock Track
·
Nov 05, 2025

Rhythm Pharmaceuticals Inc. : Oppenheimer Cuts to Perform From Outperform

THOMSON REUTERS
·
Nov 05, 2025

Oppenheimer downgrades Rhythm Pharmaceuticals (RYTM) to a Hold

TIPRANKS
·
Nov 05, 2025

Rhythm Pharmaceuticals Inc : TD Cowen Raises Target Price to $120 From $110

THOMSON REUTERS
·
Nov 05, 2025

Stock Track | Rhythm Pharmaceuticals Plummets 9.92% as Q3 Earnings Miss Expectations

Stock Track
·
Nov 04, 2025

Earnings Flash (RYTM) Rhythm Pharmaceuticals Posts Q3 Net Loss $0.82 a Share, vs. FactSet Est of $0.66 Loss

MT Newswires Live
·
Nov 04, 2025

BRIEF-Rhythm Pharmaceuticals Q3 Net Income USD -52.904 Million Vs. IBES Estimate USD -45.5 Million

Reuters
·
Nov 04, 2025